On May 14, 2025, Evercore ISI Group announced the initiation of coverage on Xenon Pharmaceuticals (XENE, Financial) with an "Outperform" rating. This marks a significant development for the company as it garners attention from a major financial services firm.
The analyst responsible for this announcement, Cory Kasimov, has set a price target of $55.00 USD for XENE. This price target indicates a positive outlook on the company's potential, though no prior price target was available for comparison.
Xenon Pharmaceuticals (XENE, Financial), listed on NASDAQ, is a biopharmaceutical company that focuses on the development of therapies aimed at addressing significant unmet medical needs in neurological disorders. The new coverage and rating by Evercore ISI Group reflect confidence in the company's strategic direction and market potential.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 14 analysts, the average target price for Xenon Pharmaceuticals Inc (XENE, Financial) is $54.71 with a high estimate of $65.00 and a low estimate of $42.00. The average target implies an upside of 86.01% from the current price of $29.42. More detailed estimate data can be found on the Xenon Pharmaceuticals Inc (XENE) Forecast page.
Based on the consensus recommendation from 17 brokerage firms, Xenon Pharmaceuticals Inc's (XENE, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
